Table 2.
Demographic data and clinical characteristics of patients with HCC
| HCC in non-cirrhotic NAFLD n (%) |
HCC in cirrhotic NAFLD n (%) |
P value | |
|---|---|---|---|
| Total | 170 (100) | 940 (100) | |
| Gender | < 0.397 | ||
| Male gender | 100 (58.8) | 520 (55.3) | |
| Female gender | 70 (41.2) | 420 (44.7) | |
| Age group | 0.008 | ||
| Age > 65 years | 110 (64.7) | 700 (74.5) | |
| Age 18–65 years | 60 (35.3) | 240 (25.5) | |
| Race | < 0.001 | ||
| Non-Hispanic white | 130 (76.4) | 800 (85.1) | |
| Non-Hispanic black | 20 (11.8) | 20 (2.1) | |
| Hispanic | 20 (11.8) | 120 (12.8) | |
| Comorbidities | |||
| Obesity | 70 (41.2) | 490 (52.1) | 0.009 |
| Morbid obesity | 20 (11.8) | 240 (25.5) | < 0.001 |
| Diabetes mellitus | 100 (58.8) | 700 (74.5) | < 0.001 |
| Hypertension | 140 (82.4) | 770 (81.9) | 0.891 |
| Hyperlipidemia | 130 (76.5) | 590 (62.8) | 0.001 |
| Smoker | 30 (17.6) | 230 (24.5) | 0.053 |
| Laboratory data | |||
| High ALT | 110 (64.7) | 600 (63.8) | 0.827 |
| Medication use | |||
| Statin | 100 (58.8) | 450 (47.9) | 0.009 |
| ACEI or ARBs | 120 (70.6) | 610 (64.9) | 0.150 |
| Metformin | 60 (35.3) | 390 (41.5) | 0.130 |
| Sulfonylurea | 40 (23.5) | 280 (39.8) | 0.097 |
| Thiazolidinedione | 0 (0) | 70 (7.4) | < 0.001 |
| Insulin | 80 (47.0) | 620 (66.0) | < 0.001 |
| Liver decompensation | – | 675 (71.8) |